These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 14977529)

  • 1. The search for new sterilizing anti-tuberculosis drugs.
    Mitchison DA
    Front Biosci; 2004 May; 9():1059-72. PubMed ID: 14977529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive in vitro models of the sterilizing activity of anti-tuberculosis drugs.
    Mitchison DA; Coates AR
    Curr Pharm Des; 2004; 10(26):3285-95. PubMed ID: 15544516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fighting tuberculosis by drugs targeting nonreplicating
    Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
    Int J Mycobacteriol; 2017; 6(3):213-221. PubMed ID: 28776518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Trends in tuberculosis treatment duration].
    Veziris N; Aubry A; Truffot-Pernot C
    Presse Med; 2006 Nov; 35(11 Pt 2):1758-1764. PubMed ID: 17086138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The resumption of consumption -- a review on tuberculosis.
    Ducati RG; Ruffino-Netto A; Basso LA; Santos DS
    Mem Inst Oswaldo Cruz; 2006 Nov; 101(7):697-714. PubMed ID: 17160276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.
    Tyagi S; Nuermberger E; Yoshimatsu T; Williams K; Rosenthal I; Lounis N; Bishai W; Grosset J
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2289-93. PubMed ID: 15917523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin Adjunctive Therapy Does Not Improve the Sterilizing Activity of the First-Line Antitubercular Regimen in Mice.
    Dutta NK; Pinn ML; Karakousis PC
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Tool to Identify Bactericidal Compounds against Vulnerable Targets in Drug-Tolerant M. tuberculosis found in Caseum.
    Sarathy JP; Xie M; Jones RM; Chang A; Osiecki P; Weiner D; Tsao WS; Dougher M; Blanc L; Fotouhi N; Via LE; Barry CE; De Vlaminck I; Sherman DR; Dartois VA
    mBio; 2023 Apr; 14(2):e0059823. PubMed ID: 37017524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.
    Lanoix JP; Betoudji F; Nuermberger E
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1091-6. PubMed ID: 26643352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update.
    Njire M; Tan Y; Mugweru J; Wang C; Guo J; Yew W; Tan S; Zhang T
    Adv Med Sci; 2016 Mar; 61(1):63-71. PubMed ID: 26521205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.
    Mitchison DA; Nunn AJ
    Am Rev Respir Dis; 1986 Mar; 133(3):423-30. PubMed ID: 2420242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis During Treatment of Human Tuberculosis.
    Walter ND; Dolganov GM; Garcia BJ; Worodria W; Andama A; Musisi E; Ayakaka I; Van TT; Voskuil MI; de Jong BC; Davidson RM; Fingerlin TE; Kechris K; Palmer C; Nahid P; Daley CL; Geraci M; Huang L; Cattamanchi A; Strong M; Schoolnik GK; Davis JL
    J Infect Dis; 2015 Sep; 212(6):990-8. PubMed ID: 25762787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the Efficacy of New Anti-Tuberculosis Drugs.
    Mitchison DA; Davies GR
    Open Infect Dis J; 2008 Dec; 2():59-76. PubMed ID: 23814629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.
    Gumbo T; Dona CS; Meek C; Leff R
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3197-204. PubMed ID: 19451303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A model-based analysis identifies differences in phenotypic resistance between in vitro and in vivo: implications for translational medicine within tuberculosis.
    Clewe O; Faraj A; Hu Y; Coates ARM; Simonsson USH
    J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):421-430. PubMed ID: 32488575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model.
    Hu Y; Pertinez H; Ortega-Muro F; Alameda-Martin L; Liu Y; Schipani A; Davies G; Coates A
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4778-85. PubMed ID: 27216065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.